Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ: LENZ )

25.22 -0.06 (-0.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LENZ Therapeutics, Inc. - Common Stock

LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval. 
Via Benzinga
Exposures Product Safety
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Why LENZ Therapeutics Stock Hit A New 52-Week High Today
Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug application. 
Via Benzinga
Exposures Product Safety
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024
LENZ stock results show that LENZ Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
Via Benzinga
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
From Lenz Therapeutics, Inc.
Via GlobeNewswire
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a... 
Via Benzinga
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study
LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary... 
Via Benzinga
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
From LENZ Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.